Difference between revisions of "Acebutolol"

(References)
(Adverse Reactions)
Line 45: Line 45:
 
*[[Bradycardia]], severe
 
*[[Bradycardia]], severe
 
*[[Heart block]]
 
*[[Heart block]]
*[[Angina]] if abrupt D/C, [[MI]] if abrupt D/C
+
*[[Angina]], [[MI]] if abrupt discontinuation
*Ventricular arrhythmia if abrupt D/C
+
*Ventricular [[arrhythmia]] if abrupt discontinuation
 
*Raynaud phenomenon
 
*Raynaud phenomenon
*[[Bronchospasm]]
+
*Bronchospasm
*Lupus erythematosus
+
*[[Lupus]] erythematosus
 
===Common===
 
===Common===
 
*[[Fatigue]], [[Dizziness]], [[Headache]]
 
*[[Fatigue]], [[Dizziness]], [[Headache]]
Line 62: Line 62:
 
*Abnormal dreams
 
*Abnormal dreams
 
*[[Rash]]
 
*[[Rash]]
*[[Arthralgia]]/Myalgia
+
*[[Arthralgia]]/[[Myalgia]]
 
*Visual disturbance
 
*Visual disturbance
  

Revision as of 16:33, 19 September 2019

Administration

  • Type: Beta blocker
  • Dosage Forms: Cap: 200mg, 400mg
  • Routes of Administration: Oral
  • Common Trade Names: Sectral

Adult Dosing

Hypertension

  • 400-800 mg PO bid
    • Max: 1200 mg/day (800mg in elderly pts)

Ventricular arrhythmia

  • 300-600 mg PO bid
    • Max: 1200 mg/day (800mg in elderly pts)

Pediatric Dosing

Safety/efficacy not established in pediatric patients

Special Populations

  • Pregnancy Rating: Possible risk of intrauterine growth restriction
  • Lactation risk: Avoid during breastfeeding

Renal Dosing

  • Adult:
    • CrCl 25-50: Decrease dose 50%
    • CrCl <25: Decrease dose 75%
    • HD/PD: No supplement
  • Pediatric: Not defined

Hepatic Dosing

  • Adult: Caution advised
  • Pediatric: Not defined

Contraindications

Adverse Reactions

Serious

Common

Pharmacology

  • Half-life: 3-4 hours (8-13h diacetolol)
  • Metabolism: Liver; Production of active metabolite (diacetolol)
  • Excretion: Bile/feces/gut wall 50-60%; Urine 30-40% (12-29% unchanged)

Mechanism of Action

  • Selectively antagonizes beta-1 adrenergic receptors
  • Class II antiarrhythmic

Comments

See Also

References

  • Acebutolol hydrochloride [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals; January 2016
  • Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society [published online ahead of print October 30, 2017]. Circulation. 2017. doi: 10.1161/CIR.0000000000000549. [PubMed 29084731]
  • American College of Obstetricians and Gynecologists (ACOG), Committee on Obstetric Practice. Committee Opinion No. 623: emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period. Obstet Gynecol. 2015;125(2):521-525. [PubMed 25611642]